Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.

Saturno G, Valenti M, De Haven Brandon A, Thomas GV, Eccles S, Clarke PA, Workman P.

Oncotarget. 2013 Aug;4(8):1185-98.

2.

HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.

Lee DH, Sung KS, Bartlett DL, Kwon YT, Lee YJ.

Cell Signal. 2015 Feb;27(2):293-305. doi: 10.1016/j.cellsig.2014.11.013. Epub 2014 Nov 18.

3.

Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.

Opel D, Naumann I, Schneider M, Bertele D, Debatin KM, Fulda S.

Clin Cancer Res. 2011 May 15;17(10):3233-47. doi: 10.1158/1078-0432.CCR-10-2530. Epub 2011 Feb 25.

4.

Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX.

Powers MV, Valenti M, Miranda S, Maloney A, Eccles SA, Thomas G, Clarke PA, Workman P.

Oncotarget. 2013 Nov;4(11):1963-75.

5.

The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.

Ui T, Morishima K, Saito S, Sakuma Y, Fujii H, Hosoya Y, Ishikawa S, Aburatani H, Fukayama M, Niki T, Yasuda Y.

Oncol Rep. 2014 Feb;31(2):619-24. doi: 10.3892/or.2013.2899. Epub 2013 Dec 5.

PMID:
24317439
6.

Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.

Oikonomou E, Koc M, Sourkova V, Andera L, Pintzas A.

PLoS One. 2011;6(6):e21632. doi: 10.1371/journal.pone.0021632. Epub 2011 Jun 27.

7.

Hsp90 inhibitors promote p53-dependent apoptosis through PUMA and Bax.

He K, Zheng X, Zhang L, Yu J.

Mol Cancer Ther. 2013 Nov;12(11):2559-68. doi: 10.1158/1535-7163.MCT-13-0284. Epub 2013 Aug 21.

8.

17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis.

Siegelin MD, Habel A, Gaiser T.

Neurobiol Dis. 2009 Feb;33(2):243-9. doi: 10.1016/j.nbd.2008.10.005. Epub 2008 Nov 10.

PMID:
19027068
9.

HSP90 inhibitor enhances anti-proliferative and apoptotic effects of celecoxib on HT-29 colorectal cancer cells via increasing BAX/BCL-2 ratio.

Mohammadi A, Yaghoobi MM, GholamhoseynianNajar A, Kalantari-Khandani B, Sharifi H, Saravani M.

Cell Mol Biol (Noisy-le-grand). 2016 Oct 31;62(12):62-67. doi: 10.14715/cmb/2016.62.12.11.

PMID:
27894402
10.

Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.

Desale SS, Raja SM, Kim JO, Mohapatra B, Soni KS, Luan H, Williams SH, Bielecki TA, Feng D, Storck M, Band V, Cohen SM, Band H, Bronich TK.

J Control Release. 2015 Jun 28;208:59-66. doi: 10.1016/j.jconrel.2015.02.001. Epub 2015 Feb 3.

12.

The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.

Floris G, Debiec-Rychter M, Wozniak A, Stefan C, Normant E, Faa G, Machiels K, Vanleeuw U, Sciot R, Schöffski P.

Mol Cancer Ther. 2011 Oct;10(10):1897-908. doi: 10.1158/1535-7163.MCT-11-0148. Epub 2011 Aug 8.

13.

17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.

Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.

Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2348-56. doi: 10.1167/iovs.07-1305. Epub 2008 Feb 15.

PMID:
18281615
14.

Targeting GRP75 improves HSP90 inhibitor efficacy by enhancing p53-mediated apoptosis in hepatocellular carcinoma.

Guo W, Yan L, Yang L, Liu X, E Q, Gao P, Ye X, Liu W, Zuo J.

PLoS One. 2014 Jan 17;9(1):e85766. doi: 10.1371/journal.pone.0085766. eCollection 2014.

15.
16.

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.

Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, Solit DB.

Cancer Res. 2008 Jan 15;68(2):589-96. doi: 10.1158/0008-5472.CAN-07-1570.

17.

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.

Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.

Clin Cancer Res. 2006 Nov 15;12(22):6826-35.

18.

Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.

Leow CC, Chesebrough J, Coffman KT, Fazenbaker CA, Gooya J, Weng D, Coats S, Jackson D, Jallal B, Chang Y.

Mol Cancer Ther. 2009 Aug;8(8):2131-41. doi: 10.1158/1535-7163.MCT-08-1038. Epub 2009 Aug 11.

19.

Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.

Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, McConkey DJ.

Cancer Res. 2007 Feb 15;67(4):1430-5.

20.

Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.

Watanabe G, Behrns KE, Kim JS, Kim RD.

Cancer Chemother Pharmacol. 2009 Aug;64(3):433-43. doi: 10.1007/s00280-008-0888-2. Epub 2008 Dec 12.

Supplemental Content

Support Center